SCI时时刷

search
+
The role of daratumumab in complications post-allogeneic hematopoietic stem cell transplantation: a single-center prospective study on PRCA and AIHA
Pure red cell aplasia (PRCA) and autoimmune hemolytic anemia (AIHA) post-hematopoietic stem cell transplantation (HSCT) ar...
Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice
Measurable residual disease (MRD) testing in patients with acute myelogenous leukemia (AML) represents a heterogenous asse...
The BLIND study: blinatumomab and DLI approach for management of B-ALL relapse after allogeneic stem cell transplantation. A multicentric Italian experience
Greil C, Engelhardt M, Ihorst G, Duque-Afonso J, Shoumariyeh K, Bertz H, et al. Prognostic factors for survival after allo...
Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice
Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice
This study is one of the first to demonstrate real-world use of BEL cGVHD combination therapy using both standard and nove...
Pretransplantation risk factors for positive MRD after allogeneic stem cell transplantation in AML patients: a prospective study
Pretransplantation risk factors for positive MRD after allogeneic stem cell transplantation in AML patients: a prospective study
We aimed to prospectively explore the risk factors for measurable residual disease (MRD) positivity after allogeneic stem ...
Successful allogeneic CD34+ hematopoietic stem cell boost for prolonged cytopenias following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. On behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC)
Rives S, Maude SL, Hiramatsu H, Baruchel A, Bader P, Bittencourt H, et al. Tisagenlecelucel in pediatric and young adult p...
Evaluation of standard fludarabine dosing and corresponding exposures in infants and young children undergoing hematopoietic cell transplantation
Evaluation of standard fludarabine dosing and corresponding exposures in infants and young children undergoing hematopoietic cell transplantation
Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002;41:93–103.Article  C...
Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia
Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia
NPM1 mutated acute myeloid leukemia (AML) comprises roughly 30% of all AML cases and is mainly classified as favorable or ...
Utility of the 2024 best practice recommendations from the EBMT Cellular Therapy and Immunobiology Working Party for use of donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation
Utility of the 2024 best practice recommendations from the EBMT Cellular Therapy and Immunobiology Working Party for use of donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation
Competing interests ACM: nothing to disclose. AP: nothing to disclose. SM: nothi...
Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma
Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma
Aggressive lymphomas are a heterogeneous group with a curative treatment approach. Advances in immunochemotherapy and salv...
Correction: Hematopoietic stem cell transplantation activity in China 2022–2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group
Correction: Hematopoietic stem cell transplantation activity in China 2022–2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group
A full list of members and their affiliations appears in the Supplementary Information.Peking University People’s Hospital...
Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial
Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial
In fit patients with newly diagnosed myeloma, high-dose chemotherapy (HDCT) followed by autologous stem cell transplantati...
Gender equality in wine and medicine
Gender equality in wine and medicine
The best kind of wine is that which is most pleasant to him who drinks it. Pli...
Correction: Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity
Correction: Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity
These authors contributed equally: Emily C. Liang, Kai Rejeski, Roni Shouval, Jordan Gauthier.Fred Hutchinson Cancer Cente...
Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Autologous hematopoietic cell transplants (auto-HCTs) remain the standard of care for transplant-eligible MM patients. The...
Strategies following failure of CAR-T-cell therapy in non-Hodgkin lymphoma
Strategies following failure of CAR-T-cell therapy in non-Hodgkin lymphoma
Several CD19 CAR-T-cell drugs are approved for safety and efficacy in advanced B-cell cancers with encouraging results. Ho...
Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Therapy-related myeloid neoplasms (t-MN) are a complication of multiple myeloma (MM) treatment. Our retrospective, EBMT re...
Role of the CIBMTR biorepository and registry in precision transplantation research
Role of the CIBMTR biorepository and registry in precision transplantation research
Observational studies using registry-based data have become indispensable in our management of patients receiving hematopo...
Fedratinib as an alternative to splenectomy for refractory splenomegaly prior to transplant for myelofibrosis
Smith E, Huang J, Viswabandya A, Maze D, Malik S, Cheung V, et al. Association of factors influencing selection of upfront...
Mismatched unrelated donors allogeneic hematopoietic stem cell transplantation with antithymocyte globulin for hematological malignancies: a multicenter retrospective study in China
Mismatched unrelated donors allogeneic hematopoietic stem cell transplantation with antithymocyte globulin for hematological malignancies: a multicenter retrospective study in China
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) utilizing mismatched unrelated donors (MMUD) present a vita...
Pre-transplant disease burden rather than age or donor type was associated with survival of hematopoietic cell transplantation for elderly patients with acute myeloid leukemia
Pre-transplant disease burden rather than age or donor type was associated with survival of hematopoietic cell transplantation for elderly patients with acute myeloid leukemia
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the best treatment for patients with intermediate- ...
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia
Measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) in complete remission is an important progno...
Monitoring and management of CMV and EBV after autologous haematopoietic stem cell transplantation for autoimmune diseases: a survey of the EBMT Autoimmune Diseases Working party (ADWP)
Monitoring and management of CMV and EBV after autologous haematopoietic stem cell transplantation for autoimmune diseases: a survey of the EBMT Autoimmune Diseases Working party (ADWP)
Monitoring of EBV viremia in auto-HCT recipients was reported by 39/51 (76%) of centres and all of them tested EBV-specifi...
Correction: Hematopoietic cell transplantation and cell therapy activity landscape survey in the Kingdom of Saudi Arabia; a report from the Saudi Society of Blood and Marrow Transplantation (SSBMT)
King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi ArabiaNaila Shaheen, Mohsen Alzahrani, Moham...
Mold infections in chronic granulomatous disease patients—what comes to the rescue?
In this issue of Bone Marrow Transplantation, Kline et al. present 26 patients with Chronic Granuloma...
Outcomes in hematopoetic cell transplantation in the setting of mold infections in patients with chronic granulomatous disease
Outcomes in hematopoetic cell transplantation in the setting of mold infections in patients with chronic granulomatous disease
Chronic granulomatous disease (CGD) is a disorder of immunity characterized by phagocyte dysfunction. Mold infections in p...
Real world outcome analysis of treosulfan-based conditioning prior to allo-HCT in patients with MDS compared to clinical trial data
Competing interests MS: Novartis: Speakers Bureau; Pfizer: Honoraria, Membership...
Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease
Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease
REACH2 and REACH3 were randomized, multicenter, open-label phase 3 studies comparing the selective Janus kinase (JAK)1/JAK...
The economic cost of care in poor graft function following allogeneic stem cell transplantation
The economic cost of care in poor graft function following allogeneic stem cell transplantation
Broder M, Quock T, Chang E, Reddy S, Agarwal-Hashmi R, Arai S, et al. The Cost of Hematopoietic Stem-Cell Transplantation ...
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia
Routine genetic profiling of acute myeloid leukemia (AML) at initial diagnosis has allowed subgroup specific prognosticati...
阅读更多
format_indent_increase